MCID: ADR007
MIFTS: 72

Adrenoleukodystrophy

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Reproductive diseases, Metabolic diseases, Endocrine diseases

Aliases & Classifications for Adrenoleukodystrophy

MalaCards integrated aliases for Adrenoleukodystrophy:

Name: Adrenoleukodystrophy 54 38 12 72 50 51 71 29 13 52 42 14 69
X-Linked Adrenoleukodystrophy 12 23 50 24 25 56
X-Ald 23 50 24 25 56
Ald 12 50 56 71
Siemerling-Creutzfeldt Disease 12 25 71
Adrenomyeloneuropathy 56 71 69
Diffuse Cerebral Sclerosis of Schilder 12 69
Addison Disease and Cerebral Sclerosis 25 71
Melanodermic Leukodystrophy 25 71
Bronze Schilder Disease 12 71
Schilder's Disease 12 51
Diffuse Sclerosis 12 51
Schilder Disease 12 25
X-Linked Cerebral Adrenoleukodystrophy 56
Encephalitis Periaxialis Concentrica 12
Encephalitis Periaxialis, Schilder's 12
Sudanophilic Cerebral Sclerosis 12
Adrenoleukodystrophy, X-Linked 24
Adrenomyeloneuropathy, Adult 54
Balo's Concentric Sclerosis 69
Schilder-Addison Complex 25
Systemic Scleroderma 69
X-Linked Ald 56
Amn 71

Characteristics:

Orphanet epidemiological data:

56
x-linked adrenoleukodystrophy
Inheritance: X-linked recessive; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: All ages;
x-linked cerebral adrenoleukodystrophy
Inheritance: X-linked recessive; Age of onset: All ages;
adrenomyeloneuropathy
Inheritance: X-linked recessive; Age of onset: Adult;

OMIM:

54
Miscellaneous:
progressive disorder
highly variable phenotype, ranging from asymptomatic to death by age 3 years
onset ranges from childhood (severe phenotype) to adulthood (limited phenotype)
heterozygous female carriers may manifest symptoms
estimated incidence of 1 in 17,000

Inheritance:
x-linked recessive


HPO:

32
adrenoleukodystrophy:
Onset and clinical course progressive
Inheritance x-linked recessive inheritance


GeneReviews:

23
Penetrance The biochemical phenotype of elevated plasma concentration of vlcfa has nearly 100% penetrance in males...

Classifications:



Summaries for Adrenoleukodystrophy

NINDS : 51 X-linked Adrenoleukodystrophy (ALD) is one of a group of genetic disorders called the leukodystrophies that cause damage to the myelin sheath, an insulating membrane that surrounds nerve cells in the brain. Women have two X chromosomes and are the carriers of the disease, but since men only have one X chromosome and lack the protective effect of the extra X chromosome, they are more severely affected.  People with X-ALD accumulate high levels of saturated, very long chain fatty acids (VLCFA) in the brain and adrenal cortex. The loss of myelin and the progressive dysfunction of the adrenal gland are the primary characteristics of X-ALD. While nearly all patients with X-ALD suffer from adrenal insufficiency, also known as Addison's disease, the neurological symptoms can begin either in childhood or in adulthood. The childhood cerebral form is the most severe, with onset between ages 4 and 10. The most common symptoms are usually behavioral changes such as abnormal withdrawal or aggression, poor memory, and poor school performance. Other symptoms include visual loss, learning disabilities, seizures, poorly articulated speech, difficulty swallowing, deafness, disturbances of gait and coordination, fatigue, intermittent vomiting, increased skin pigmentation, and progressive dementia. The milder adult-onset form is also known as adrenomyeloneuropathy (AMN), which typically begins between ages 21 and 35.  Symptoms may include progressive stiffness, weakness or paralysis of the lower limbs, and ataxia. Although adult-onset ALD progresses more slowly than the classic childhood form, it can also result in deterioration of brain function. Almost half the women who are carriers of X-ALS will develop a milder form of AMN but almost never will develop symptoms seen in boys the X-ALD.  X-ALD should not be confused with neonatal adrenoleukodsystrophy, which is a disease of newborns and young infants and belongs to the group of peroxisomal biogenesis disorders.

MalaCards based summary : Adrenoleukodystrophy, also known as x-linked adrenoleukodystrophy, is related to peroxisome biogenesis disorder 1b and neonatal adrenoleukodystrophy, and has symptoms including visual impairment, diplopia and headache. An important gene associated with Adrenoleukodystrophy is ABCD1 (ATP Binding Cassette Subfamily D Member 1), and among its related pathways/superpathways are Peroxisome and PPAR signaling pathway. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and adrenal gland, and related phenotype is homeostasis/metabolism.

NIH Rare Diseases : 50 x-linked adrenoleukodystrophy (x-ald) is an inherited condition that occurs mostly in males.  the condition mainly affects the nervous system and the adrenal glands (small glands located on top of each kidney). people with this disorder often have progressive destruction of the fatty covering (myelin) that insulates nerves in the brain and spinal cord. they may also have a shortage of certain hormones caused by damage to the outer layer of the adrenal glands (adrenal cortex), called adrenocortical insufficiency.  x-ald is caused by mutations in the abcd1 gene. these gene mutations cause a shortage (deficiency) of a protein called adrenoleukodystrophy protein (aldp).  a deficiency of this protein leads to an abnormally high level of fat molecules called very long-chain fatty acids (vlcfa) to build up in the body.  high levels of vlcfa may be toxic to the adrenal cortex and myelin.  there are several forms of x-ald including: a childhood cerebral form, an adrenomyeloneuropathy (amn) type, and an adrenal insufficiency-only type. another form of ald is occasionally seen in women who are carriers of the condition a specific treatment for x-ald is not currently available, but eating a diet low in vlcfa and taking special oils can lower the blood levels of vlcfa. bone marrow transplantation (bmt) may be an option for boys and adolescents in early stages who have evidence of brain involvement on mri.  adrenocortical insufficiency is treated with cortisone replacement. last updated: 8/6/2013

UniProtKB/Swiss-Prot : 71 Adrenoleukodystrophy: A peroxisomal metabolic disorder characterized by progressive multifocal demyelination of the central nervous system and by peripheral adrenal insufficiency (Addison disease). It results in mental deterioration, corticospinal tract dysfunction, and cortical blindness. Different clinical manifestations exist like: cerebral childhood ALD (CALD), adult cerebral ALD (ACALD), adrenomyeloneuropathy (AMN) and 'Addison disease only' (ADO) phenotype.

Genetics Home Reference : 25 X-linked adrenoleukodystrophy is a genetic disorder that occurs primarily in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. In this disorder, the fatty covering (myelin) that insulates nerves in the brain and spinal cord is prone to deterioration (demyelination), which reduces the ability of the nerves to relay information to the brain. In addition, damage to the outer layer of the adrenal glands (adrenal cortex) causes a shortage of certain hormones (adrenocortical insufficiency). Adrenocortical insufficiency may cause weakness, weight loss, skin changes, vomiting, and coma.

OMIM : 54
Adrenoleukodystrophy is an X-linked disorder which is secondary to a mutation in the ABCD1 gene and results in the apparent defect in peroxisomal beta oxidation and the accumulation of the saturated very long chain fatty acids (VLCFA) in all tissues of the body. The manifestations of the disorder occur primarily in the adrenal cortex, the myelin of the central nervous system, and the Leydig cells of the testes. ABCD1 is an ATPase binding cassette protein in the same category of transporter proteins such as the CFTR and MDR proteins. Identification of X-ALD as a lipid-storage disease, as a defect in the capacity to degrade VLCFAs, and its characterization as a peroxisomal disorder was reviewed by Moser (1997). Moser et al. (2005) provided a clinical review of ALD. (300100)

Disease Ontology : 12 A leukodystrophy that disrupts the breakdown of very-long-chain fatty acids resulting in progressive brain damage, failure of the adrenal glands and eventually death.

Wikipedia : 72 Adrenoleukodystrophy is a disease linked to the X chromosome. It is a result of fatty acid buildup... more...

GeneReviews: NBK1315

Related Diseases for Adrenoleukodystrophy

Diseases related to Adrenoleukodystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Related Disease Score Top Affiliating Genes
1 peroxisome biogenesis disorder 1b 32.8 PEX1 PEX10
2 neonatal adrenoleukodystrophy 12.2
3 childhood-onset cerebral x-linked adrenoleukodystrophy 12.2
4 peroxisomal acyl-coa oxidase deficiency 11.7
5 mitochondrial dna depletion syndrome 4a 11.2
6 balo concentric sclerosis 11.2
7 tumefactive multiple sclerosis 11.2
8 adrenomyeloneuropathy 11.2
9 leukodystrophy 11.1
10 zellweger syndrome 11.0
11 spasticity 11.0
12 peroxisome biogenesis disorder 11b 10.8
13 peroxisome biogenesis disorder 2b 10.8
14 peroxisome biogenesis disorders, zellweger syndrome spectrum 10.8
15 d-bifunctional protein deficiency 10.8
16 peroxisome biogenesis disorder 3b 10.8
17 peroxisome biogenesis disorder 4b 10.8
18 peroxisome biogenesis disorder 7b 10.8
19 peroxisome biogenesis disorder 6b 10.8
20 peroxisome biogenesis disorder 1a 10.8
21 peroxisome biogenesis disorder 5b 10.8
22 peroxisome biogenesis disorder 11a 10.6
23 peroxisome biogenesis disorder 8a 10.6
24 peroxisome biogenesis disorder 8b 10.6
25 peroxisome biogenesis disorder 2a 10.6
26 peroxisome biogenesis disorder 3a 10.6
27 peroxisome biogenesis disorder 4a 10.6
28 peroxisomal beta-oxidation disorder 10.6
29 peroxisome biogenesis disorder 9b 10.6
30 peroxisome biogenesis disorder 7a 10.6
31 peroxisome biogenesis disorder 6a 10.6
32 peroxisome biogenesis disorder 10a 10.6
33 peroxisome biogenesis disorder 13a 10.6
34 peroxisome biogenesis disorder 5a 10.6
35 sudanophilic cerebral sclerosis 10.6
36 wells-jankovic syndrome 10.6
37 peroxisome biogenesis disorder 12a 10.6
38 myelinoclastic diffuse sclerosis 10.6
39 cerebritis 10.5
40 deafness hypospadias metacarpal and metatarsal syndrome 10.3 PEX1 PEX6
41 chronic erosive gastritis 10.3 ABCD1 BCAP31
42 congenital disorder of glycosylation, type iig 10.2 ACOX1 PEX5
43 spinocerebellar ataxia, x-linked 1 10.2 ABCD1 BCAP31
44 pfeiffer mayer syndrome 10.2 ABCD1 PEX1 PEX5
45 growth hormone deficiency, isolated, type ia 10.1 PEX1 PEX5
46 addison's disease 10.1
47 hematopoietic stem cell transplantation 10.0
48 peroxisomal disease 9.9
49 spinocerebellar degeneration 9.9
50 peroxisome disorders 9.9

Graphical network of the top 20 diseases related to Adrenoleukodystrophy:



Diseases related to Adrenoleukodystrophy

Symptoms & Phenotypes for Adrenoleukodystrophy

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
ataxia
white matter abnormalities
spasticity
seizures
loss of speech
more
Neurologic- Behavioral Psychiatric Manifestations:
psychosis
autistic features
attention deficit-hyperactivity disorder
behavioral changes

Head And Neck- Eyes:
loss of vision

Neurologic- Peripheral Nervous System:
sensory loss
distal axonopathy (adrenomyeloneuropathy)

Endocrine Features:
adrenal insufficiency (addison disease)

Head And Neck- Ears:
hearing loss

Genitourinary- Bladder:
urinary incontinence

Genitourinary- External Genitalia Male:
impotence

Abdomen- Gastroin testinal:
fecal incontinence

Laboratory- Abnormalities:
systemic accumulation of very long chain fatty acids (vlcfa)


Clinical features from OMIM:

300100

Human phenotypes related to Adrenoleukodystrophy:

56 32 (show top 50) (show all 56)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual impairment 56 32 hallmark (90%) Very frequent (99-80%) HP:0000505
2 diplopia 56 32 occasional (7.5%) Occasional (29-5%) HP:0000651
3 headache 56 32 hallmark (90%) Very frequent (99-80%) HP:0002315
4 intellectual disability 56 32 hallmark (90%) Very frequent (99-80%) HP:0001249
5 aggressive behavior 56 32 frequent (33%) Frequent (79-30%) HP:0000718
6 neurogenic bladder 56 32 frequent (33%) Frequent (79-30%) HP:0000011
7 hemiparesis 56 32 frequent (33%) Frequent (79-30%) HP:0001269
8 aphasia 56 32 frequent (33%) Frequent (79-30%) HP:0002381
9 dementia 56 32 hallmark (90%) Very frequent (99-80%) HP:0000726
10 disinhibition 56 32 frequent (33%) Frequent (79-30%) HP:0000734
11 impotence 56 32 occasional (7.5%) Occasional (29-5%) HP:0000802
12 paraparesis 56 32 Very frequent (99-80%) HP:0002385
13 incoordination 56 32 Very frequent (99-80%) HP:0002311
14 gait disturbance 56 32 hallmark (90%) Very frequent (99-80%) HP:0001288
15 visual loss 56 32 hallmark (90%) Very frequent (99-80%) HP:0000572
16 visual field defect 56 32 frequent (33%) Frequent (79-30%) HP:0001123
17 sensory impairment 56 32 hallmark (90%) Very frequent (99-80%) HP:0003474
18 adrenal insufficiency 56 32 frequent (33%) Frequent (79-30%) HP:0000846
19 clumsiness 56 32 hallmark (90%) Very frequent (99-80%) HP:0002312
20 increased intracranial pressure 56 32 frequent (33%) Frequent (79-30%) HP:0002516
21 paralysis 56 32 occasional (7.5%) Occasional (29-5%) HP:0003470
22 attention deficit hyperactivity disorder 56 32 hallmark (90%) Very frequent (99-80%) HP:0007018
23 inappropriate sexual behavior 56 32 frequent (33%) Frequent (79-30%) HP:0008768
24 abnormality of metabolism/homeostasis 56 32 hallmark (90%) Very frequent (99-80%) HP:0001939
25 urinary bladder sphincter dysfunction 56 32 frequent (33%) Frequent (79-30%) HP:0002839
26 specific learning disability 56 32 hallmark (90%) Very frequent (99-80%) HP:0001328
27 increased circulating acth level 56 32 frequent (33%) Frequent (79-30%) HP:0003154
28 progressive hearing impairment 56 32 hallmark (90%) Very frequent (99-80%) HP:0001730
29 functional motor problems 56 32 hallmark (90%) Very frequent (99-80%) HP:0004302
30 progressive spastic paraparesis 56 32 hallmark (90%) Very frequent (99-80%) HP:0007199
31 leg muscle stiffness 56 32 hallmark (90%) Very frequent (99-80%) HP:0008969
32 cognitive impairment 56 Very frequent (99-80%)
33 spastic paraplegia 32 HP:0001258
34 seizures 32 HP:0001250
35 loss of speech 32 HP:0002371
36 blindness 32 HP:0000618
37 hyperactivity 56 Very frequent (99-80%)
38 truncal ataxia 32 HP:0002078
39 limb ataxia 32 HP:0002070
40 psychosis 32 HP:0000709
41 urinary incontinence 32 HP:0000020
42 hypogonadism 32 HP:0000135
43 neurodegeneration 32 HP:0002180
44 polyneuropathy 32 HP:0001271
45 slurred speech 32 HP:0001350
46 hearing impairment 32 HP:0000365
47 elevated long chain fatty acids 32 HP:0003455
48 bulbar palsy 32 HP:0001283
49 primary adrenal insufficiency 32 HP:0008207
50 bowel incontinence 32 HP:0002607

UMLS symptoms related to Adrenoleukodystrophy:


exanthema, pruritus, hidebound skin, ataxia, muscle spasticity, seizures, paraparesis, absence of sensation, abnormal coordination, unspecified visual loss

MGI Mouse Phenotypes related to Adrenoleukodystrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.32 ABCB6 ABCD1 ABCD2 ABCD3 ACOX1 EHHADH

Drugs & Therapeutics for Adrenoleukodystrophy

Drugs for Adrenoleukodystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
3
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
5
Glycerol Approved, Investigational Phase 2, Phase 3 56-81-5 753
6
Biotin Approved, Nutraceutical Phase 2, Phase 3 58-85-5 171548
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8
Betaine Approved, Nutraceutical Phase 3 107-43-7 247
9 Micronutrients Phase 2, Phase 3,Phase 1
10 Trace Elements Phase 2, Phase 3,Phase 1
11 Vitamin B Complex Phase 2, Phase 3
12 Vitamins Phase 2, Phase 3,Phase 1
13 Bile Acids and Salts Phase 3
14 Cholic Acids Phase 3
15 Gastrointestinal Agents Phase 3
16 Liver Extracts Phase 3
17 Alkylating Agents Phase 2, Phase 3
18 Antilymphocyte Serum Phase 2, Phase 3
19 Antirheumatic Agents Phase 2, Phase 3
20 Immunosuppressive Agents Phase 2, Phase 3
21 Methylprednisolone acetate Phase 2, Phase 3
22 Methylprednisolone Hemisuccinate Phase 2, Phase 3
23 Prednisolone acetate Phase 2, Phase 3
24 Prednisolone hemisuccinate Phase 2, Phase 3
25 Prednisolone phosphate Phase 2, Phase 3
26 Antimetabolites Phase 3,Phase 2
27 Hypolipidemic Agents Phase 3
28 Lipid Regulating Agents Phase 3
29 Pharmaceutical Solutions Phase 2, Phase 3
30 Folate Nutraceutical Phase 2, Phase 3
31 Vitamin B7 Nutraceutical Phase 2, Phase 3
32 Vitamin B9 Nutraceutical Phase 2, Phase 3
33
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
34
alemtuzumab Approved, Investigational Phase 2 216503-57-0
35
Benzocaine Approved Phase 2 1994-09-7, 94-09-7 2337
36
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
37
Hydroxyurea Approved Phase 2 127-07-1 3657
38
Melphalan Approved Phase 2 148-82-3 4053 460612
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
41
Mycophenolic acid Approved Phase 2 24280-93-1 446541
42
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
43
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
44
rituximab Approved Phase 2 174722-31-7 10201696
45 Thiotepa Approved Phase 2 52-24-4 5453
46
Mesna Approved Phase 2 3375-50-6 598
47 Tocopherol Approved, Nutraceutical Phase 2
48
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
49 tannic acid Approved, Nutraceutical Phase 2
50
Cholecalciferol Approved, Nutraceutical Phase 1, Phase 2 67-97-0 6221 10883523 5280795

Interventional clinical trials:

(show all 36)

id Name Status NCT ID Phase Drugs
1 MD1003-AMN MD1003 in Adrenomyeloneuropathy Completed NCT02961803 Phase 2, Phase 3 MD1003 100 mg capsule;Placebo
2 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
3 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
4 Betaine and Peroxisome Biogenesis Disorders Completed NCT01838941 Phase 3 Betaine
5 A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Recruiting NCT01896102 Phase 2, Phase 3
6 A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Not yet recruiting NCT03231878 Phase 2, Phase 3 MIN-102;Placebos
7 Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy Suspended NCT00004418 Phase 2, Phase 3 glyceryl trierucate;glyceryl trioleate
8 A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Terminated NCT00545597 Phase 3 Lorenzo's oil
9 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
10 A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Completed NCT01495260 Phase 2 N-acetylcysteine;lipoic acid;vitamin E
11 HSCT for High Risk Inherited Inborn Errors Completed NCT00383448 Phase 2 Clofarabine;Melphalan;Alemtuzumab;mycophenylate mofetil;Hydroxyurea
12 A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Recruiting NCT02595489 Phase 1, Phase 2
13 Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Recruiting NCT02559830 Phase 1, Phase 2
14 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2 IMD Preparative Regimen;Osteopetrosis Only Preparative Regimen;Osteopetrosis Haploidentical Only Preparative Regimen;cALD SR-A (Standard-Risk, Regimen A);cALD SR-B (Standard-Risk, Regimen B);cALD HR-D (High-Risk, Regimen C);cALD HR-D (High-Risk, Regimen D)
15 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
16 Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Active, not recruiting NCT01043640 Phase 2 Campath-1H;Cyclophosphamide;Busulfan;Cyclosporine A;Mycophenolate Mofetil
17 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
18 Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Not yet recruiting NCT03196765 Phase 1, Phase 2 Sobetirome
19 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
20 Human Placental-Derived Stem Cell Transplantation Recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
21 MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Withdrawn NCT02410239 Phase 1
22 Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Withdrawn NCT01787578 Phase 1 Sobetirome
23 Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Unknown status NCT00278044
24 Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT00005900
25 The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) Completed NCT01165060 Bezafibrate
26 Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Completed NCT01594853
27 Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Completed NCT00004450 glyceryl trierucate;glyceryl trioleate;interferon beta;thalidomide
28 Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders Completed NCT01626092 Campath-1H;Clofarabine;Melphalan;Cyclosporine A;Mycophenolate mofetil
29 Newborn Screening for Adrenoleukodystrophy Recruiting NCT02952482
30 Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) Recruiting NCT02204904
31 Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy Available NCT02233257 Lorenzo's Oil
32 Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants Available NCT01881334
33 Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Enrolling by invitation NCT02698579
34 A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Not yet recruiting NCT03278899
35 Early Diagnosis Of Childhood Cerebral ALD Not yet recruiting NCT02948062
36 Study of Bile Acids in Patients With Peroxisomal Disorders Terminated NCT00004442 chenodeoxycholic acid;cholic acid;ursodiol

Search NIH Clinical Center for Adrenoleukodystrophy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adrenoleukodystrophy cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: adrenoleukodystrophy

Genetic Tests for Adrenoleukodystrophy

Genetic tests related to Adrenoleukodystrophy:

id Genetic test Affiliating Genes
1 Adrenoleukodystrophy 29
2 Adrenoleukodystrophy, X-Linked 24 ABCD1

Anatomical Context for Adrenoleukodystrophy

MalaCards organs/tissues related to Adrenoleukodystrophy:

39
Brain, Cortex, Adrenal Gland, Adrenal Cortex, Skin, Bone, Kidney

Publications for Adrenoleukodystrophy

Articles related to Adrenoleukodystrophy:

(show top 50) (show all 720)
id Title Authors Year
1
A first case of adrenomyeloneuropathy with mutation Y174S of the adrenoleukodystrophy gene. ( 28456143 )
2017
2
Beam Me In: Thyroid Hormone Analog Targets Alternative Transporter in Mouse Model of X-Linked Adrenoleukodystrophy ( 28609836 )
2017
3
Neurocognitive Trajectory of Boys Who Received a Hematopoietic Stem Cell Transplant at an Early Stage of Childhood Cerebral Adrenoleukodystrophy. ( 28418523 )
2017
4
Lipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy. ( 28666219 )
2017
5
X-linked adrenoleukodystrophy in a chimpanzee due to an ABCD1 mutation reported in multiple unrelated humans. ( 28919002 )
2017
6
Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy. ( 28725571 )
2017
7
Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy. ( 28288261 )
2017
8
Heat shock protein expression in cerebral X-linked adrenoleukodystrophy reveals astrocyte stress prior to myelin loss. ( 28319253 )
2017
9
A zebrafish model of X-linked adrenoleukodystrophy recapitulates key disease features and demonstrates a developmental requirement for abcd1 in oligodendrocyte patterning and myelination. ( 28911205 )
2017
10
Quality of life among boys with adrenoleukodystrophy following hematopoietic stem cell transplant. ( 28934891 )
2017
11
Decision Making in Adrenoleukodystrophy: When Is a Good Outcome Really a Good Outcome? ( 28418445 )
2017
12
Long-term outcome of patients with X-linked adrenoleukodystrophy: A retrospective cohort study. ( 28274546 )
2017
13
A Thyroid Hormone-Based Strategy for Correcting the Biochemical Abnormality in X-Linked Adrenoleukodystrophy. ( 28200172 )
2017
14
Activation of Cerebral X-linked Adrenoleukodystrophy After Head Trauma. ( 28534457 )
2017
15
Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. ( 28004277 )
2017
16
Inflammatory profile in X-linked adrenoleukodystrophy patients: Understanding disease progression. ( 28722826 )
2017
17
Unmasking adrenoleukodystrophy in a cohort of cerebellar ataxia. ( 28481932 )
2017
18
Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. ( 28375456 )
2017
19
New insights into adrenoleukodystrophy. ( 28552315 )
2017
20
A novel mutation in ABCD1 unveils different clinical phenotypes in a family with adrenoleukodystrophy. ( 28601575 )
2017
21
Therapeutic strategies in adrenoleukodystrophy. ( 28493141 )
2017
22
Venture Philanthropy and Gene Therapy: Lessons from Adrenoleukodystrophy. ( 26784642 )
2016
23
MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy. ( 26843114 )
2016
24
Mild phenotype in an adult male with X-linked adrenoleukodystrophy - case report. ( 26862418 )
2016
25
Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome. ( 27991992 )
2016
26
X-linked adrenoleukodystrophy presenting with positional downbeat nystagmus. ( 27272035 )
2016
27
Synthetic cannabinoids revealing adrenoleukodystrophy. ( 26601810 )
2016
28
A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy. ( 26836218 )
2016
29
A case of adrenoleukodystrophy presenting with manic symptoms in a patient on steroids for Addison's disease. ( 28197008 )
2016
30
An ABCD1 Mutation (c.253dupC) Caused Diverse Phenotypes of Adrenoleukodystrophy in an Iranian Consanguineous Pedigree. ( 27489563 )
2016
31
The ABCD's of 5'-adenosine monophosphate-activated protein kinase and adrenoleukodystrophy. ( 26990533 )
2016
32
The Clinical Features and Diagnosis of Adrenoleukodystrophy: A Case Series of Iranian Family. ( 27057190 )
2016
33
A de-novo large deletion of 2.8 kb produced in the ABCD1 gene causing adrenoleukodystrophy disease. ( 27248780 )
2016
34
Middle cerebellar peduncle sign in adrenoleukodystrophy. ( 27147183 )
2016
35
Simultaneous Testing for 6 Lysosomal Storage Disorders and X-Adrenoleukodystrophy in Dried Blood Spots by Tandem Mass Spectrometry. ( 27440509 )
2016
36
Endocrine Dysfunction in X-Linked Adrenoleukodystrophy. ( 27241966 )
2016
37
A selective detection of lysophosphatidylcholine in dried blood spots for diagnosis of adrenoleukodystrophy by LC-MS/MS. ( 27331004 )
2016
38
Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. ( 27312864 )
2016
39
Neurodegeneration in a Drosophila model of adrenoleukodystrophy: the roles of the Bubblegum and Double bubble acyl-CoA synthetases. ( 26893370 )
2016
40
CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. ( 27425035 )
2016
41
Novel Therapeutic Targets and Drug Candidates for Modifying Disease Progression in Adrenoleukodystrophy. ( 26684655 )
2016
42
Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. ( 27337030 )
2016
43
Metformin-induced mitochondrial function and ABCD2 up regulation in X-linked adrenoleukodystrophy involves AMP activated protein kinase. ( 26849413 )
2016
44
C26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man. ( 27124591 )
2016
45
Generation of human embryonic stem cells from abnormal blastocyst diagnosed with adrenoleukodystrophy. ( 27934597 )
2016
46
25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome. ( 27779191 )
2016
47
Childhood Cerebral Adrenoleukodystrophy: MR Perfusion Measurements and Their Use in Predicting Clinical Outcome after Hematopoietic Stem Cell Transplantation. ( 27079370 )
2016
48
A Hierarchical Bayesian Approach for Combining Pharmacokinetic/Pharmacodynamic Modeling and Phase IIa Trial Design in Orphan Drugs: Treating Adrenoleukodystrophy with Lorenzo's Oil. ( 27547896 )
2016
49
Brain Lipotoxicity of Phytanic Acid and Very Long-chain Fatty Acids. Harmful Cellular/Mitochondrial Activities in Refsum Disease and X-Linked Adrenoleukodystrophy. ( 27114847 )
2016
50
Astrocytes and mitochondria from adrenoleukodystrophy protein (ABCD1)-deficient mice reveal that the adrenoleukodystrophy-associated very long-chain fatty acids target several cellular energy-dependent functions. ( 25583114 )
2015

Variations for Adrenoleukodystrophy

UniProtKB/Swiss-Prot genetic disease variations for Adrenoleukodystrophy:

71 (show top 50) (show all 138)
id Symbol AA change Variation ID SNP ID
1 ABCD1 p.Ser98Leu VAR_000024
2 ABCD1 p.Arg104Cys VAR_000025
3 ABCD1 p.Arg104His VAR_000026
4 ABCD1 p.Thr105Ile VAR_000027
5 ABCD1 p.Leu107Pro VAR_000028
6 ABCD1 p.Ser108Trp VAR_000029
7 ABCD1 p.Gly116Arg VAR_000030 rs398123110
8 ABCD1 p.Ala141Thr VAR_000033 rs193922097
9 ABCD1 p.Asn148Ser VAR_000034 rs128624216
10 ABCD1 p.Ser149Asn VAR_000035
11 ABCD1 p.Arg152Cys VAR_000036
12 ABCD1 p.Arg152Pro VAR_000037
13 ABCD1 p.Arg163His VAR_000038
14 ABCD1 p.Tyr174Asp VAR_000039 rs128624217
15 ABCD1 p.Tyr174Ser VAR_000040
16 ABCD1 p.Gln178Glu VAR_000041
17 ABCD1 p.Tyr181Cys VAR_000042
18 ABCD1 p.Arg182Pro VAR_000043
19 ABCD1 p.Asp194His VAR_000044
20 ABCD1 p.Asp200Val VAR_000045
21 ABCD1 p.Leu211Pro VAR_000046
22 ABCD1 p.Leu220Pro VAR_000047
23 ABCD1 p.Asp221Gly VAR_000048
24 ABCD1 p.Thr254Met VAR_000049
25 ABCD1 p.Thr254Pro VAR_000050
26 ABCD1 p.Pro263Leu VAR_000051
27 ABCD1 p.Gly266Arg VAR_000052 rs128624218
28 ABCD1 p.Lys276Glu VAR_000053
29 ABCD1 p.Gly277Arg VAR_000054
30 ABCD1 p.Gly277Trp VAR_000056
31 ABCD1 p.Glu291Asp VAR_000057
32 ABCD1 p.Glu291Lys VAR_000058 rs128624213
33 ABCD1 p.Ala294Thr VAR_000060
34 ABCD1 p.Ser342Pro VAR_000061
35 ABCD1 p.Arg389Gly VAR_000062 rs128624215
36 ABCD1 p.Arg389His VAR_000063
37 ABCD1 p.Arg401Gln VAR_000064 rs128624219
38 ABCD1 p.Arg418Trp VAR_000065 rs128624220
39 ABCD1 p.Pro484Arg VAR_000066 rs128624214
40 ABCD1 p.Gly507Val VAR_000067
41 ABCD1 p.Gly512Ser VAR_000068
42 ABCD1 p.Ser515Phe VAR_000069 rs128624223
43 ABCD1 p.Arg518Gln VAR_000070 rs398123102
44 ABCD1 p.Arg518Trp VAR_000071 rs128624224
45 ABCD1 p.Gly522Trp VAR_000072
46 ABCD1 p.Pro534Leu VAR_000074
47 ABCD1 p.Pro560Leu VAR_000075 rs398123105
48 ABCD1 p.Pro560Arg VAR_000076
49 ABCD1 p.Met566Lys VAR_000077
50 ABCD1 p.Arg591Gln VAR_000078

ClinVar genetic disease variations for Adrenoleukodystrophy:

6 (show top 50) (show all 54)
id Gene Variation Type Significance SNP ID Assembly Location
1 ABCD1 NM_000033.3(ABCD1): c.871G> A (p.Glu291Lys) single nucleotide variant Pathogenic rs128624213 GRCh37 Chromosome X, 152991592: 152991592
2 ABCD1 NM_000033.3(ABCD1): c.1451C> G (p.Pro484Arg) single nucleotide variant Pathogenic rs128624214 GRCh37 Chromosome X, 153002668: 153002668
3 ABCD1 ABCD1, IVS6AS, A-G, -2 single nucleotide variant Pathogenic
4 ABCD1 ABCD1, IVS8AS, G-A, -10, 8-BP INS insertion Pathogenic
5 ABCD1 NM_000033.3(ABCD1): c.1165C> G (p.Arg389Gly) single nucleotide variant Pathogenic rs128624215 GRCh37 Chromosome X, 153001649: 153001649
6 ABCD1 NM_000033.3(ABCD1): c.443A> G (p.Asn148Ser) single nucleotide variant Pathogenic rs128624216 GRCh37 Chromosome X, 152991164: 152991164
7 ABCD1 NM_000033.3(ABCD1): c.520T> G (p.Tyr174Asp) single nucleotide variant Pathogenic rs128624217 GRCh37 Chromosome X, 152991241: 152991241
8 ABCD1 NM_000033.3(ABCD1): c.796G> A (p.Gly266Arg) single nucleotide variant Pathogenic rs128624218 GRCh37 Chromosome X, 152991517: 152991517
9 ABCD1 NM_000033.3(ABCD1): c.1202G> A (p.Arg401Gln) single nucleotide variant Pathogenic rs128624219 GRCh37 Chromosome X, 153001686: 153001686
10 ABCD1 NM_000033.3(ABCD1): c.1252C> T (p.Arg418Trp) single nucleotide variant Pathogenic rs128624220 GRCh37 Chromosome X, 153001826: 153001826
11 ABCD1 NM_000033.3(ABCD1): c.1390C> T (p.Arg464Ter) single nucleotide variant Pathogenic rs128624221 GRCh37 Chromosome X, 153001964: 153001964
12 ABCD1 NM_000033.3(ABCD1): c.1415_1416delAG (p.Gln472Argfs) deletion Pathogenic rs387906494 GRCh37 Chromosome X, 153002632: 153002633
13 ABCD1 NM_000033.3(ABCD1): c.1429G> T (p.Glu477Ter) single nucleotide variant Pathogenic rs128624222 GRCh37 Chromosome X, 153002646: 153002646
14 ABCD1 NM_000033.3(ABCD1): c.1544C> T (p.Ser515Phe) single nucleotide variant Pathogenic rs128624223 GRCh37 Chromosome X, 153005601: 153005601
15 ABCD1 NM_000033.3(ABCD1): c.1552delC (p.Arg518Glyfs) deletion Pathogenic rs387906495 GRCh37 Chromosome X, 153005609: 153005609
16 ABCD1 NM_000033.3(ABCD1): c.1552C> T (p.Arg518Trp) single nucleotide variant Pathogenic rs128624224 GRCh37 Chromosome X, 153005609: 153005609
17 ABCD1 ABCD1, IVS6DS, G-A, +1 single nucleotide variant Pathogenic
18 ABCD1 ABCD1, 2-BP DEL, 2177TA deletion Pathogenic
19 ABCD1 NM_000033.3(ABCD1): c.1817C> T (p.Ser606Leu) single nucleotide variant Pathogenic rs128624225 GRCh37 Chromosome X, 153008477: 153008477
20 ABCD1 NM_000033.3(ABCD1): c.1850G> A (p.Arg617His) single nucleotide variant Pathogenic rs11146842 GRCh37 Chromosome X, 153008510: 153008510
21 ABCD1 NM_000033.3(ABCD1): c.1849C> T (p.Arg617Cys) single nucleotide variant Pathogenic rs4010613 GRCh37 Chromosome X, 153008509: 153008509
22 ABCD1 NM_000033.3(ABCD1): c.871_873delGAG (p.Glu292del) deletion Pathogenic rs387906496 GRCh37 Chromosome X, 152991592: 152991594
23 ABCD1 ABCD1, IVS8DS, G-A, +1 single nucleotide variant Pathogenic
24 ABCD1 ABCD1, IVS1DS, G-A, -1 single nucleotide variant Pathogenic
25 ABCD1 NM_000033.3(ABCD1): c.-18_8del26 (p.Met1_Gly66del) deletion Pathogenic rs387906497 GRCh37 Chromosome X, 152990704: 152990729
26 ABCD1 NM_000033.3(ABCD1): c.1366dupC (p.Arg456Profs) duplication Likely pathogenic rs193922093 GRCh37 Chromosome X, 153001940: 153001940
27 ABCD1 NM_000033.3(ABCD1): c.1592T> C (p.Leu531Pro) single nucleotide variant Likely pathogenic rs193922094 GRCh37 Chromosome X, 153005649: 153005649
28 ABCD1 NM_000033.3(ABCD1): c.421G> A (p.Ala141Thr) single nucleotide variant Pathogenic rs193922097 GRCh37 Chromosome X, 152991142: 152991142
29 ABCD1 NM_000033.3(ABCD1): c.838C> T (p.Arg280Cys) single nucleotide variant Likely pathogenic rs193922098 GRCh37 Chromosome X, 152991559: 152991559
30 ABCD1 NM_000033.3(ABCD1): c.1396C> T (p.Gln466Ter) single nucleotide variant Pathogenic rs398123100 GRCh37 Chromosome X, 153002613: 153002613
31 ABCD1 NM_000033.3(ABCD1): c.1553G> A (p.Arg518Gln) single nucleotide variant Pathogenic rs398123102 GRCh37 Chromosome X, 153005610: 153005610
32 ABCD1 NM_000033.3(ABCD1): c.1586G> A (p.Gly529Asp) single nucleotide variant Likely pathogenic rs398123103 GRCh37 Chromosome X, 153005643: 153005643
33 ABCD1 NM_000033.3(ABCD1): c.1660C> A (p.Arg554Ser) single nucleotide variant Likely pathogenic rs398123104 GRCh37 Chromosome X, 153006053: 153006053
34 ABCD1 NM_000033.3(ABCD1): c.1679C> T (p.Pro560Leu) single nucleotide variant Pathogenic rs398123105 GRCh37 Chromosome X, 153006072: 153006072
35 ABCD1 NM_000033.3(ABCD1): c.1771C> T (p.Arg591Trp) single nucleotide variant Pathogenic/Likely pathogenic rs398123106 GRCh37 Chromosome X, 153006164: 153006164
36 ABCD1 NM_000033.3(ABCD1): c.1802G> A (p.Trp601Ter) single nucleotide variant Pathogenic rs398123107 GRCh37 Chromosome X, 153008462: 153008462
37 ABCD1 NM_000033.3(ABCD1): c.1866-10G> A single nucleotide variant Pathogenic rs398123108 GRCh37 Chromosome X, 153008665: 153008665
38 ABCD1 NM_000033.3(ABCD1): c.31_46del16 (p.Arg11Serfs) deletion Pathogenic rs398123109 GRCh37 Chromosome X, 152990752: 152990767
39 ABCD1 NM_000033.3(ABCD1): c.346G> A (p.Gly116Arg) single nucleotide variant Pathogenic rs398123110 GRCh37 Chromosome X, 152991067: 152991067
40 ABCD1 NM_000033.3(ABCD1): c.406C> T (p.Gln136Ter) single nucleotide variant Pathogenic rs398123111 GRCh37 Chromosome X, 152991127: 152991127
41 ABCD1 NM_000033.3(ABCD1): c.498_520del23 (p.Val167Leufs) deletion Pathogenic rs398123112 GRCh37 Chromosome X, 152991219: 152991241
42 ABCD1 NM_000033.3(ABCD1): c.614C> A (p.Ala205Glu) single nucleotide variant Likely pathogenic rs398123113 GRCh37 Chromosome X, 152991335: 152991335
43 ABCD1 NM_000033.3(ABCD1): c.253_254insC (p.Arg85Profs) insertion Pathogenic rs713993050 GRCh38 Chromosome X, 153725519: 153725519
44 ABCD1 NM_000033.3(ABCD1): c.1661G> A (p.Arg554His) single nucleotide variant Pathogenic rs201568579 GRCh38 Chromosome X, 153740600: 153740600
45 ABCD1 NM_000033.3(ABCD1): c.1825G> A (p.Glu609Lys) single nucleotide variant Pathogenic rs150346282 GRCh38 Chromosome X, 153743031: 153743031
46 ABCD1 NM_000033.3(ABCD1): c.1201C> G (p.Arg401Gly) single nucleotide variant Likely pathogenic rs727503786 GRCh37 Chromosome X, 153001685: 153001685
47 ABCD1 NM_000033.3(ABCD1): c.887A> G (p.Tyr296Cys) single nucleotide variant Pathogenic rs797044610 GRCh37 Chromosome X, 152991608: 152991608
48 ABCD1 NM_000033.3(ABCD1): c.886T> C (p.Tyr296His) single nucleotide variant Likely pathogenic rs797044611 GRCh37 Chromosome X, 152991607: 152991607
49 ABCD1 NM_000033.3(ABCD1): c.2006_2007delAC (p.His669Leufs) deletion Pathogenic rs797044625 GRCh37 Chromosome X, 153008957: 153008958
50 ABCD1 NM_000033.3(ABCD1): c.1992-2A> G single nucleotide variant Pathogenic rs797044626 GRCh37 Chromosome X, 153008941: 153008941

Expression for Adrenoleukodystrophy

Search GEO for disease gene expression data for Adrenoleukodystrophy.

Pathways for Adrenoleukodystrophy

GO Terms for Adrenoleukodystrophy

Cellular components related to Adrenoleukodystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.86 ABCB6 ABCD1 ABCD3 ACOX1 BCAP31 EHHADH
2 peroxisome GO:0005777 9.77 ABCD1 ABCD2 ABCD3 ABCD4 ACOX1 EHHADH
3 peroxisomal matrix GO:0005782 9.54 ABCD3 ACOX1 EHHADH
4 integral component of peroxisomal membrane GO:0005779 9.46 ABCD1 PEX10 PEX26 SLC27A2
5 ATP-binding cassette (ABC) transporter complex GO:0043190 9.4 ABCB6 ABCD4
6 peroxisomal membrane GO:0005778 9.4 ABCD1 ABCD2 ABCD3 ABCD4 ACOX1 PEX1
7 membrane GO:0016020 10.17 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 ACOX1
8 cytosol GO:0005829 10.13 ABCB6 ABCD1 ABCD2 ABCD3 BCAP31 EHHADH

Biological processes related to Adrenoleukodystrophy according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.95 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 PEX19
2 fatty acid metabolic process GO:0006631 9.7 ACOX1 EHHADH SLC27A2
3 fatty acid beta-oxidation using acyl-CoA oxidase GO:0033540 9.58 ABCD1 ACOX1 EHHADH
4 protein import into peroxisome matrix GO:0016558 9.56 PEX1 PEX10 PEX26 PEX5
5 protein targeting to peroxisome GO:0006625 9.54 PEX1 PEX19 PEX6
6 alpha-linolenic acid metabolic process GO:0036109 9.51 ABCD1 ACOX1
7 protein import into peroxisome membrane GO:0045046 9.5 PEX19 PEX26 PEX5
8 fatty acid beta-oxidation GO:0006635 9.5 ABCD1 ABCD2 ABCD3 ACOX1 EHHADH PEX5
9 very long-chain fatty acid metabolic process GO:0000038 9.49 ABCD2 ACOX1
10 peroxisomal long-chain fatty acid import GO:0015910 9.46 ABCD1 ABCD3
11 very long-chain fatty acid catabolic process GO:0042760 9.46 ABCD1 ABCD2 ABCD3 SLC27A2
12 peroxisome organization GO:0007031 9.17 ABCD1 ABCD3 PEX1 PEX10 PEX19 PEX5
13 transport GO:0006810 10.09 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 BCAP31

Molecular functions related to Adrenoleukodystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.86 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 PEX1
2 enzyme binding GO:0019899 9.73 ABCD1 EHHADH PEX5 SLC27A2
3 protein C-terminus binding GO:0008022 9.63 PEX1 PEX26 PEX6
4 protein complex binding GO:0032403 9.62 BCAP31 PEX1 PEX26 PEX6
5 protein N-terminus binding GO:0047485 9.58 ACOX1 PEX19 PEX5
6 ATPase activity GO:0016887 9.43 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4 PEX6
7 ATPase activity, coupled GO:0042623 9.37 PEX1 PEX6
8 long-chain fatty acid transporter activity GO:0005324 9.33 ABCD1 ABCD2 ABCD3
9 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.02 ABCB6 ABCD1 ABCD2 ABCD3 ABCD4

Sources for Adrenoleukodystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....